What is the appropriate evaluation and management for vasculitis affecting the legs?

Evaluation and Management of Vasculitis Affecting the Legs

For vasculitis affecting the legs, establish the diagnosis through skin biopsy and ANCA testing, categorize disease severity, and treat with immunosuppression tailored to whether disease is organ-threatening or limited to the skin.

Initial Diagnostic Evaluation

Obtain a skin biopsy from the most tender, reddish or purpuric lesion extending to the subcutis to confirm vasculitis and determine vessel size involvement 1. Serial sections are often required to identify the main vasculitic lesion 2. The biopsy should be performed whenever vasculitis is suspected, as histopathological evidence is strongly supportive of the diagnosis 1.

Essential Laboratory Testing

• Perform ANCA testing (both indirect immunofluorescence and ELISA) in the appropriate clinical context 1. ANCA positivity suggests ANCA-associated vasculitis (AAV) including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic granulomatosis with polyangiitis (EGPA) 1.

• Obtain direct immunofluorescence on biopsy tissue to distinguish IgA-associated vasculitis (Henoch-Schönlein purpura) from IgG-/IgM-associated vasculitis, which has prognostic significance 2.

• Conduct structured clinical assessment, urinalysis, and basic laboratory tests including inflammatory markers (ESR, CRP), complete blood count, comprehensive metabolic panel, and renal function 1.

Exclude Vasculitis Mimics

Rule out pseudovasculitis conditions such as antiphospholipid antibody syndrome and other thrombotic disorders 2. Consider screening for anticardiolipin antibodies, particularly in patients with livedoid vasculitis patterns 3.

Disease Severity Categorization

Categorize patients with ANCA-associated vasculitis according to disease severity to guide treatment decisions 1. This distinction is critical:

• Organ-threatening or life-threatening disease: Renal involvement (creatinine >3.4 mg/dL, rapidly rising creatinine, or dialysis requirement), pulmonary hemorrhage with hypoxemia, or other major organ involvement 1

• Non-organ threatening disease: Limited cutaneous manifestations without systemic involvement 1

Treatment Approach

For Systemic ANCA-Associated Vasculitis with Leg Involvement

Remission Induction

Use rituximab or cyclophosphamide combined with glucocorticoids for remission induction in generalized AAV 1. The 2024 KDIGO guidelines establish this as the standard approach.

• Rituximab dosing: 375 mg/m² weekly for 4 weeks OR 1000 mg on days 1 and 15 1
• Cyclophosphamide dosing: 15 mg/kg IV every 2-4 weeks (adjust for age and renal function) 1
• Glucocorticoid dosing: High-dose therapy is essential; typically methylprednisolone 1 mg/kg/day (maximum 60 mg/day) 1

Consider plasma exchange for patients with severe renal disease (SCr >3.4 mg/dL or requiring dialysis) or diffuse alveolar hemorrhage with hypoxemia 1.

Maintenance Therapy

Following remission induction, use either rituximab or azathioprine with low-dose glucocorticoids for maintenance 1. This is a grade 1C recommendation from KDIGO 2024.

Maintenance duration should be 18 months to 4 years after induction of remission 1:

• Rituximab: 500 mg × 2 at complete remission, then 500 mg at months 6,12, and 18 (MAINRITSAN scheme) 1
• Azathioprine: 1.5-2 mg/kg/day at complete remission, maintained for 18-24 months, then decreased to 1 mg/kg/day until 4 years, then taper by 25 mg every 3 months 1
• Glucocorticoids: Continue at 5-7.5 mg/day for 2 years, then slowly reduce by 1 mg every 2 months 1

For patients intolerant of azathioprine, consider mycophenolate mofetil (2000 mg/day in divided doses) or methotrexate as alternatives 1. Note that methotrexate should not be used if GFR <60 ml/min/1.73 m² 1.

For Non-Organ Threatening Cutaneous Vasculitis

Use methotrexate (oral or parenteral) combined with glucocorticoids as a less toxic alternative to cyclophosphamide for non-organ threatening ANCA-associated vasculitis 1. This is a grade 1B recommendation with level B strength.

For mild, self-limited cutaneous vasculitis without systemic involvement:

• Conservative measures: Leg elevation, avoidance of prolonged standing, warming, and avoidance of cold temperatures 4, 2
• First-line pharmacotherapy: NSAIDs or antihistamines for symptomatic relief 4, 5
• For mild recurrent or persistent disease: Colchicine or dapsone are first-choice agents 1, 4, 2

Refractory or Relapsing Disease

Patients with relapsing disease should be reinduced, preferably with rituximab 1.

For refractory disease, increase glucocorticoids (IV or oral), add rituximab if cyclophosphamide was used previously (or vice versa), and consider plasma exchange 1.

Alternative options for progressive disease despite optimal therapy include mycophenolate mofetil, intravenous immunoglobulin, or biologic agents 1.

Special Considerations and Monitoring

Manage patients with primary small and medium vessel vasculitis in collaboration with or at centers of expertise 1. This is particularly important given the complexity of these conditions.

Use structured clinical assessment, urinalysis, and laboratory monitoring at each clinical visit 1. This ongoing surveillance is essential for detecting relapse and monitoring treatment toxicity.

Important Caveats

• Cyclophosphamide carries significant bladder cancer risk; investigate persistent unexplained hematuria in patients with prior cyclophosphamide exposure 1
• Screen for IgA deficiency before administering IVIG to prevent anaphylactic reactions 1
• Provide bone protection therapy for all patients on long-term glucocorticoids 1
• Consider Pneumocystis jiroveci prophylaxis during intensive immunosuppression 1